These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1600053)

  • 21. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
    Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
    Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
    Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
    Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The acidity index: a simple approach to the measurement of gastric acidity.
    Tutuian R; Castell DO; Xue S; Katz PO
    Aliment Pharmacol Ther; 2004 Feb; 19(4):443-8. PubMed ID: 14871284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole.
    Lanzon-Miller S; Pounder RE; Hamilton MR; Ball S; Chronos NA; Raymond F; Olausson M; Cederberg C
    Aliment Pharmacol Ther; 1987 Jun; 1(3):239-51. PubMed ID: 2979226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of pantoprazole on endocrine function in healthy male volunteers.
    Dammann HG; Bethke T; Burkhardt F; Wolf N; Khalil H; Luehmann R
    Aliment Pharmacol Ther; 1994 Oct; 8(5):549-54. PubMed ID: 7865648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects.
    Geus WP; Mathôt RA; Mulder PG; Lamers CB
    Aliment Pharmacol Ther; 2000 Aug; 14(8):1057-64. PubMed ID: 10930900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel proton pump inhibitor pantoprazole elevates intragastric pH for a prolonged period when administered under conditions of stimulated gastric acid secretion in the gastric fistula dog.
    Postius S; Bräuer U; Kromer W
    Life Sci; 1991; 49(14):1047-52. PubMed ID: 1832475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy.
    McColl KE; Nujumi AM; Dorrian CA; Macdonald AM; Fullarton GM; Harwood J
    Scand J Gastroenterol; 1992; 27(2):93-8. PubMed ID: 1532864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers.
    Bruley des Varannes S; Levy P; Lartigue S; Dellatolas F; Lemaire M; Galmiche JP
    Aliment Pharmacol Ther; 1994 Jun; 8(3):309-14. PubMed ID: 7918926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pantoprazole and 24-hour intragastric acidity.
    Hartmann M; Bliesath H; Lühmann R; Wurst W
    Aliment Pharmacol Ther; 1993 Feb; 7(1):115-6. PubMed ID: 8439633
    [No Abstract]   [Full Text] [Related]  

  • 31. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.
    Miehlke S; Madisch A; Kirsch C; Lindner F; Kuhlisch E; Laass M; Knoth H; Morgner A; Labenz J
    Aliment Pharmacol Ther; 2005 Apr; 21(8):963-7. PubMed ID: 15813831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.
    Hartmann M; Huber R; Bliesath H; Steinijans VW; Koch HJ; Wurst W; Kunz K
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S67-71. PubMed ID: 8793605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of SK&F 94482 (BMY-25368) on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects.
    Gavey CJ; Smith JT; Nwokolo CU; Pounder RE
    Aliment Pharmacol Ther; 1989 Dec; 3(6):557-64. PubMed ID: 2577500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of famotidine, 40 mg at night, on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects.
    Lanzon-Miller S; Pounder RE; Ball SG; Dalgleish DJ; Coward J; Jackson AO
    Scand J Gastroenterol; 1988 Mar; 23(2):244-50. PubMed ID: 3283919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
    Metz DC; Amer F; Hunt B; Vakily M; Kukulka MJ; Samra N
    Aliment Pharmacol Ther; 2006 Apr; 23(7):985-95. PubMed ID: 16573801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
    Goldstein JL; Miner PB; Schlesinger PK; Liu S; Silberg DG
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1189-96. PubMed ID: 16611280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival of the probiotic, L. plantarum 299v and its effects on the faecal bacterial flora, with and without gastric acid inhibition.
    Goossens D; Jonkers D; Russel M; Thijs A; van den Bogaard A; Stobberingh E; Stockbrügger R
    Dig Liver Dis; 2005 Jan; 37(1):44-50. PubMed ID: 15702859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease.
    Metz DC; Pratha V; Martin P; Paul J; Maton PN; Lew E; Pisegna JR
    Am J Gastroenterol; 2000 Mar; 95(3):626-33. PubMed ID: 10710049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
    Howden CW; Ballard ED; Koch FK; Gautille TC; Bagin RG
    J Clin Gastroenterol; 2009 Apr; 43(4):323-6. PubMed ID: 18758373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin.
    Duursema L; Müller FO; Schall R; Middle MV; Hundt HK; Groenewoud G; Steinijans VW; Bliesath H
    Br J Clin Pharmacol; 1995 Jun; 39(6):700-3. PubMed ID: 7654493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.